Gradient Denervation Technologies Announces Acceptance into FDA's Total Product Life Cycle Advisory Program for Development of its Pulmonary Artery Denervation System
The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations.
The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures.
'We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,' said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies. 'There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.'
About Gradient Denervation TechnologiesGradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use.
For more information, please visit: https://www.gradientdenervation.com.
CONTACT: Media Contact contact@gradientdenervation.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Smoking Cessation Aid Cytisinicline Could Soon Get FDA Approval
There are multiple smoking cessation products on the market. But there hasn't been a new approval of ... More a pharmacotherapy without nicotine in nearly 20 years. This could change soon, as cytisinicline was submitted to the FDA for approval on June 26, 2025. More than two-thirds of American smokers say they want to quit. However, besides nicotine replacement therapies, there are at present only two smoking cessation drugs without nicotine that are authorized for marketing by the Food and Drug Administration. This could change soon, as the pharmaceutical firm Achieve Life Sciences submitted to the FDA a new drug application last week for its prescription medicine, cytisinicline, also known as cytisine. The agency will review the medication's efficacy, safety, and tolerability profile based on evidence from two large, placebo-controlled Phase 3 clinical trials. The substance is a naturally occurring plant-based alkaloid that selectively binds to nicotinic receptors in the brain. In turn, this can help alleviate nicotine cravings and reduce withdrawal symptoms, among smokers of combustible cigarettes as well as e-cigarettes (vaping). Cytisinicline has been used as a smoking cessation product for decades in some Central and Eastern European countries. It was approved by the British Medicines and Healthcare products Regulatory Agency in March 2019, though only available commercially in the United Kingdom since January 2024. Cytisinicline hasn't yet been approved by the European Medicines Agency. The Journal of the American Medical Association Internal Medicine published results from one of two Phase 3 trials evaluating cytisinicline for smoking cessation. The authors' conclusions reaffirmed cytisinicline's efficacy and tolerability for smoking cessation in adult smokers at both 6- and 12-week treatment durations, including reduction in nicotine cravings and extended cessation benefits through 24 weeks. Additionally, a study published in 2024 suggested cytisinicline could be effective for e-cigarette cessation. Owing to its mechanism of action as a way to reduce nicotine dependence, it's possible that cytisinicline could be beneficial for individuals using nicotine pouches who wish to stop, though this hasn't yet been examined specifically. Based on a technology assessment of the benefits and costs of cytisinicline, the British cost-effectiveness watchdog, the National Institute for Health and Care Excellence, recommended earlier this year adding the drug to the National Health Service as a treatment option for smoking cessation. And this week, the American Institute for Clinical and Economic Review announced it is conducting an evidence review to assess the clinical effectiveness of cytisinicline together with behavior support. The evaluation will include comparisons with other existing smoking cessation products. Smoking is the leading cause of preventable death in the U.S. Cigarette smoking is responsible for more than 480,000 deaths annually in the U.S. The major causes of death associated with smoking include cardiovascular diseases such as strokes and heart attacks; cancers, among which lung, pancreatic, esophageal, bladder, colorectal and renal; and pulmonary conditions such as chronic obstructive lung disease, pneumonia and bronchitis. Last October, the FDA and the National Institutes of Health convened a public meeting to address the urgency for developing novel smoking cessation products to assist individuals of all ages, including underserved and vulnerable populations, to stop smoking. There is unmet need in this space, reflected in the fact that of the 15 million who tried to quit smoking in 2022, five in six failed, according to STAT News. Experts cite a lack of sufficiently effective smoking cessation drugs. Should cytisinicline become available in the U.S. it could represent an important option for those who wish to quit their nicotine habit. At the same time, it will continue to be critical for healthcare providers and public health authorities to raise awareness around the importance of smoking cessation and prevention, provide behavior support (counseling) and offer treatment alternatives people can use to quit. The U.S. has made real progress since the 1960s in reducing cigarette smoking, mainly through effective public health campaigns. Yet there's still a lot more work to do as roughly 29 million adults smoke combustible cigarettes and approximately 17 million use e-cigarettes. But under the Trump administration the Department of Health and Human Services has cut funding for smoking cessation and prevention programs, as well as eliminated the Centers for Disease Control and Prevention's Office on Smoking and Health. While the CDC says it will continue to provide resources for those who wish to quit smoking while conducting ongoing surveillance, experts warn that cuts in services could limit access, which could then result in a resurgence in smoking rates.
Newsweek
8 hours ago
- Newsweek
FDA Issues Most-Serious Risk Warning for Cucumber Recall
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The federal Food and Drug Administration (FDA) has classified a series of recalls for cucumber featuring products, all produced by Houston-based company JFE Franchising Inc., as Class I; this means consuming any item risks causing "serious adverse health consequences or death." Newsweek contacted JFE Franchising Inc. for comment on Saturday via online inquiry form outside of regular office hours. Why It Matters The official FDA website says that a Class I recall means there is "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." What To Know The recalls were initially issued for products containing cucumbers that "have the potential to be contaminated with Salmonella" and applies to products distributed to Alabama, Illinois, Indiana, Kentucky, Michigan, Tennessee and Wisconsin. The initial recalls took place voluntarily at the manufacturer's request in cooperation with the FDA and were announced on May 20, 2025. Products covered by the recall were all sold in plastic containers under the SNOWFRUIT or SNOWFOX label, and their respective retail numbers are: Fruit & Vegetable Tray—64 oz. 63912394047 Family Garden Salad—24 oz. 63912388065 Garden Salad—12 oz. 63912388067 Family Cobb Salad—22 oz. 63912388068 Cobb Salad—11 oz. 63912388069 Chef Salad—11 oz. 63912395033 Cucumber with Ranch—9 oz. 63912395020 Cucumber, Lime & Tajin—19oz 63912388053 Mixed Melon, Cucumbers & Tajin—18oz 63912394007 Watermelon & Cucumber w/ Tajin—18oz 63912394036 Small Vegetable Tray—19.5 oz. 63912388045 Small Party Tray with Dip—19 oz. 63912388046 Large Vegetable Tray—42 oz. 63912388056 Cucumber Slices w/Tajin—15 oz. 63912388022 Vegetable Bowl—26 oz. 63912388044 Cucumber Bowl w/ Ranch Dressing—15 oz. 63912388063 Vegetable Bowl—13 oz. 63912388072 Baby Carrot, Cucumber, & Ranch—15 oz. 63912394045 Cucumber Salad—3oz 63912389243 Spicy Cucumber Salad—3oz 63912389329 Bibimbap Bowl—13 oz. 63912389259 Yaki Noodle Bowl—12 oz. 63912389254 Ebi Vermicelli Bowl—13oz 63912389334 Sushi containing cucumber—Various price, weight and UPCs—Made daily with a one-day shelf life, already expired. The recall also applies to a number of products sold at Roundy's or Weis Market retail locations. These are: Signature Vegetable Bowl—28 oz. 639123600172 Chef Salad—16 oz. 639123600295 Cobb Style Salad—15 oz. 639123600318 Garden Salad—16 oz. 639123600547 Greek Salad—16 oz. 639123600523 Cucumber Salad—3oz 63912389205 Consumers with impacted SNOWFRUIT or SNOWFOX products are advised not to consume them but instead to return them to the place of purchase for a refund. Those with questions can contact the brands via hello@ or hello@ Stock photo: A sliced-up cucumber is seen on a chopping board, May 26, 2011 in Hamburg, Germany. Stock photo: A sliced-up cucumber is seen on a chopping board, May 26, 2011 in Hamburg, Germany. Joern Pollex/GETTY In its initial recall notice, the FDA said no illnesses related to the products had been recorded thus far. Separately, the FDA has issued a recall notice for Peak Cocktails, a popular ready-to-drink alcohol-free cocktail brand, over fears their cans could burst unexpectedly. Wegmans Semi-Sweet Chocolate Nonpareils have been recalled from stores in eight states and Washington, D.C., due to undeclared milk allergens, which the company warned could be "life-threatening" for some people. Costco has recalled Danby brand U-shaped window Air Conditioners sold between June 10, 2021 and February 2, 2022, with customers urged to stop using the products immediately. What People Are Saying The FDA said: "Salmonella is an organism that can cause serious and sometimes-fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. "In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. Symptoms of salmonellosis usually start 6 hours to 6 days after infection and last 4 to 7 days." What Happens Next Anyone who has purchased products covered by the recall are urged to dispose of them or return them to the place of purchase for a full refund.
New York Post
9 hours ago
- New York Post
I'm a neuroscientist — the ‘genuinely terrible' research that scares me the most about caffeine
Do you take your coffee with cream, sugar — or a side of brain damage? 'Caffeine in the neuroscience literature is genuinely terrible when combined with other drugs,' warned Dr. Natashia Swalve, a behavioral neuroscience professor at Grand Valley State University, in a recent TikTok. One drug in particular has her especially alarmed, with early research suggesting it may pose hazardous risks when mixed with even small amounts of the stimulant. Advertisement 5 Coffee is the most common source of caffeine for US adults. Izabela Magier – Roughly 90% of US adults consume some form of caffeine daily. The natural stimulant revs up the central nervous system, boosting alertness, focus and energy levels. The FDA considers up to 400 milligrams a day — about four or five 8-ounce cups of coffee — safe for healthy adults. Advertisement But that safety threshold flies out the window when caffeine starts interacting with other drugs in your system. 'Caffeine actually increases the toxicity of blow, and it potentially increases the toxicity of ADHD meds,' Swalve said. 'When combined with molly, it is particularly dangerous.' 5 Molly acts as both a stimulant and hallucinogen. blackday – Advertisement Molly — also known as MDMA or ecstasy — is a synthetic psychoactive drug that floods the brain with serotonin, dopamine and norepinephrine, triggering euphoria, sharpened senses, increased sociability and a rush of energy. In recent years, MDMA has gained attention as a potential therapeutic tool, but it's still widely used recreationally at music festivals, nightclubs, raves and house parties. National surveys estimate that 7.5% of Americans over the age of 12 have tried molly at least once. But the feel-good high comes at a cost. The drug can bring on a host of adverse effects, including rapid heartbeat, muscle cramping and nausea. Advertisement It also disrupts the body's ability to regulate temperature — essentially cranking up its internal thermostat — which can lead to a dangerous and sometimes fatal condition known as hyperthermia. 5 Consuming molly raises your core body temperature — and caffeine can intensify the effect. dragonstock – 'In animal and cell studies, caffeine makes the hyperthermic effect of molly … far worse,' Swalve said. While caffeine alone doesn't typically affect body temperature, research in rats shows that combining it with MDMA significantly increases both the peak temperature and the duration of the hyperthermic response — making users much more vulnerable to overheating. 'Caffeine also can increase the other problematic effects of molly,' Swalve said. 'It can actually make the drug more neurotoxic, killing off those serotonin neurons in your brain.' Serotonin plays a wide range of important roles in the body, supporting mood, sleep, digestion, appetite and even blood clotting and wound healing. Animal studies show MDMA has the potential to inflict long-term damage on serotonin neurons, which may lead to memory issues, cognitive decline and mood disorders. Advertisement 5 Caffeine amplifies the effects of molly, potentially leading to dangerously high serotonin levels. Anusorn – 'Caffeine combined with molly might be even worse for those neurons, but the problem is that none of these studies have actually been translated into humans,' Swalve said. And it doesn't take much to trigger the reaction. Swalve notes that the interaction between caffeine and molly can occur at very low doses — like the amount in a chocolate bar or a third of a can of Coke. Advertisement 'We think these things might interact in very dangerous ways, but we can't actually really tell,' she said. 'Right now we have no research in humans, and that is what actually scares me.' Other potential risks of combining molly and caffeine include an increased risk of cardiovascular issues, depression, anxiety and serotonin syndrome — a life-threatening condition marked by confusion, high fever and a rapid heart rate. In one study, mixing caffeine with molly increased the party drug's lethality from 22% to 34% in rats. Advertisement 'This is a huge problem,' Swalve said. 'Barely anyone is thinking about the Red Bull they're having while driving to that festival and how that might interact with the drugs they're taking later.' 5 Molly is one of the most well-known and frequently used club drugs. Yuri Arcurs/ – Although several studies have looked at caffeine-MDMA interactions in animals and cells, researchers have run into roadblocks when attempting to test the combination in humans. Among them: molly is considered a Schedule I substance under federal law. These drugs are considered to have a high potential for abuse and no accepted medical use. Advertisement That has made it difficult for researchers to not only obtain molly, but also secure the funding and approvals necessary for such studies. Ethical concerns also come into play. The potential dangers of combining two powerful stimulants raise major red flags about participant safety in clinical trials — and make recruiting test subjects even harder. So, as scientists work to understand the short- and long-term consequences of mixing caffeine with other drugs, Americans will continue to sip, sniff, smoke and swallow a cocktail of prescription and recreational substances — often with little clue about the risks. 'I can't guarantee that any of those together are safe,' Swalve said. 'You probably are not even considering those interactions.'
